Fewer Bottles, Fewer Applications – and Fewer Dollars!
In 2015, we are launching a portfolio of proprietary combination eye drops. This new campaign, which is branded LessDrops™, has the promise of requiring up to 50% fewer drops to be administered by patients and may provide a significant cost savings of up to 75% compared to current traditional post-surgery eye drop treatments.
Our initial offering will be our proprietary Tri-Moxi, Pred-Moxi, Pred-Ketor and Pred-Moxi-Ketor formulations as combination topical eye drops for patients following LASIK, cataract and other ocular surgeries. As the year progresses, we will round out our portfolio of eye drops, delivering new high quality, innovative prescription choices for physicians and their patients. For more information please click here.
Ophthalmology Market Opportunity
Our proprietary formulations have broad application in ocular surgeries, including the multi-billion dollarglobal ophthalmic drug market which is expected to reach an estimated value of $21.6 billion in 2018. Cataract surgery is one of the most common surgical procedures, and a 2013 Market Scope report states that 22 million procedures were performed globally in 2013, and 3.6 million procedures in the US.1 Over half of Americans require some form of vision correction and approximately 43 million of them are candidates for refractive surgery. Nearly 96% of refractive procedures performed today are LASIK (laser in situ keratomileusis), an outpatient surgical procedure used to treat nearsightedness, farsightedness, and astigmatism. Over 35 million LASIK procedures have been worldwide since receiving FDA approval in 1999, with an estimated 700,000 being performed annually in the US.2
Renata Stone, MBA
Chief Executive Officer
Dougherty Laser Vision
805-987-5300 Extension 7028